Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24

Rhea-AI Summary

Axonics, Inc. (NASDAQ: AXNX) will announce its fourth quarter and fiscal year 2021 financial results on February 24, 2022, after market close. A conference call to discuss these results will take place at 4:30 p.m. Eastern Time, accessible via call or webcast. Axonics, recognized as the fastest-growing medical technology company by Deloitte’s 2021 Technology Fast 500™, develops innovative treatments for bladder and bowel dysfunction. Their rechargeable sacral neuromodulation system effectively addresses overactive bladder and fecal incontinence, while Bulkamid offers durable relief for stress urinary incontinence.

Positive

• Ranked No. 1 on Deloitte's 2021 Technology Fast 500.
• Innovative products for overactive bladder and fecal incontinence.
• Established reimbursement coverage in the U.S. and Europe.

Negative

• None.

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter and fiscal year 2021 financial results after the market closes on Thursday, February 24, 2022.

In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-5771 (U.S.) or 409-217-8725 (international) and using passcode 6189042.

A live webcast of the conference call may be accessed by visiting the Events & Presentations section of the Axonics investor relations website. A replay of the webcast will be available shortly after the conclusion of the conference call and will be archived on the Axonics website.

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.

The company’s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics’ best-in-class urethral bulking agent, Bulkamid^®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005002/en/

Neil Bhalodkar

949-336-5293

ir@axonics.com

Source: Axonics, Inc.

FAQ

When will Axonics report its Q4 and fiscal year 2021 financial results?

Axonics will report its financial results on February 24, 2022.

What time is the Axonics conference call for Q4 results?

The conference call will be held at 4:30 p.m. Eastern Time.

How can I access the Axonics conference call for Q4 results?

You can access the call by dialing 866-687-5771 (U.S.) or 409-217-8725 (international) and using passcode 6189042.

What innovative products does Axonics offer?

Axonics offers a rechargeable sacral neuromodulation system and Bulkamid for bladder and bowel dysfunction.

What demographic is affected by overactive bladder and fecal incontinence?

Approximately 87 million adults in the U.S. and Europe suffer from overactive bladder, with an additional 40 million experiencing fecal incontinence.